Induction of adaptive anti-HER2/neu immune responses in a phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): A trial coordinated by the Eastern Cooperative Oncology Group

Journal of Immunotherapy

Volumn 30, Issue 4, 2007, Pages 455-467

  Borghaei, Hossein ^a   Katherine Alpaugh, R ^a   Bernardo, Patricia ^b   Palazzo, Irma E ^a   Dutcher, Janice P ^c   Venkatraj, Usha ^d,e   Wood, William C ^f   Goldstein, Lori ^a   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c OUR LADY OF MERCY MEDICAL CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e Hope Cancer Clinic   (United States)

^f EMORY UNIVERSITY   (United States)

Author keywords

Bispecific antibody; HER2 neu; Immunization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2B1; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADULT; AGED; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL MEDIATED CYTOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; LEUKOPENIA; METASTASIS; NAUSEA; PRIORITY JOURNAL; PROTEIN DOMAIN; RIGOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CANCER VACCINES; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 34247586058     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31803bb421     Document Type: Article

References (55)

1. Miller RA, Maloney DG, Warnke R, et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517-522.
2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
3. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol. 2002;29(2 suppl 6):18-22.
4. Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol. 2002;29(1 suppl 2):81-86.
5. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
6. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
7. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.
8. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-3684.
9. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241-247.
10. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
11. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
12. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
13. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6:29-31.
14. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
15. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
16. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234-3243.
17. Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results (Abstract). Proc ASCO. 2002;21:35.
18. Reuben JM, Lee BN, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006;106:2437-2444.
19. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3:611-618.
20. Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29:455-463.
21. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-2191.
22. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
23. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-799.
24. Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science. 1983;221:865-867.
25. Heijnen IA, van de Winkel JG. Human IgG Fc receptors. Int Rev Immunol. 1997;16:29-55.
26. Sulica A, Morel P, Metes D, et al. Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int Rev Immunol. 2001;20:371-414.
27. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758.
28. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940-3947.
29. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-446.
30. Segal DM, Wunderlich JR. Targeting of cytotoxic cells with heterocrosslinked antibodies. Cancer Invest. 1988;6:83-92.
31. Lanzavecchia A, Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol. 1987;17:105-111.
32. Renner C, Jung W, Sahin U, et al. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur J Immunol. 1995;25:2027-2033.
33. Shen L, Guyre PM, Anderson CL, et al. Heteroantibody-mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-gamma and is not blocked by human IgG. J Immunol. 1986;137:3378-3382.
34. de Palazzo IG, Gercel-Taylor C, Kitson J, et al. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes. Cancer Res. 1990;50:7123-7128.
35. Weiner LM, Holmes M, Richeson A, et al. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol. 1993;151:2877-2886.
36. Hsieh-Ma ST, Eaton AM, Shi T, et al. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fcγ receptor III. Cancer Res. 1992;52:6832-6839.
37. Sconocchia G, Titus JA, Segal DM. CD44 is a cytotoxic triggering molecule in human peripheral blood NK cells. J Immunol. 1994; 153:5473-5481.
38. Weiner LM, Holmes M, Adams GP, et al. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res. 1993;53:94-100.
39. Weiner GJ, Kostelny SA, Hillstrom JR, et al. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol. 1994;152:2385-2392.
40. Titus JA, Perez P, Kaubisch A, et al. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol. 1987;139:3153-3158.
41. Hombach A, Jung W, Pohl C, et al. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer. 1993;55:830-836.
42. Valone FH, Kaufman PA, Guyre PM, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol. 1995;13:2281-2292.
43. Goldstein J, Graziano RF, Sundarapandiyan K, et al. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64)x epidermal growth factor bispecific fusion protein. J Immunol. 1997;158:872-879.
44. Pullarkat V, Deo Y, Link J, et al. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunol Immunother. 1999;48:9-21.
45. James ND, Atherton PJ, Jones J, et al. A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2 + advanced prostate cancer. Br J Cancer. 2001;85:152-156.
46. Curnow RT. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother. 1997;45:210-215.
47. Ring DB, Shi T, Hsieh-Ma ST, et al. Targeted lysis of human breast cancer cells by human effector cells armed with bispecific antibody 2B1 (anti-c-erbB-2/anti-Fcg receptor III). In: Ceriani R, ed. Proceedings of the Fourth International Workshop on Monoclonal Antibodies and Breast Cancer. San Francisco, California, New York: Plenum Publishing Corp; 1991.
48. Weiner LM, Clark JI, Davey M, et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 1995;55:4586-4593.
49. Clark JI, Alpaugh RK, von Mehren M, et al. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol Immunother. 1997;44:265-272.
50. Disis ML, Knutson KL, Schiffman K, et al. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat. 2000;62:245-252.
51. Repp R, van Ojik HH, Valerius T, et al. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer. 2003;89:2234-2243.
52. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest. 2002;110:71-79.
53. Shi T, Eaton AM, Ring DB. Selection of hybrid hybridomas by flow cytometry using a new combination of fluorescent vital stains. J Immunol Methods. 1991;141:165-175.
54. Kaplan-Meier. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
55. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253.